FDA Approves Dako Assays as CDx for Genentech's Breast Cancer Treatment | GenomeWeb

NEW YORK (GenomeWeb News) – Dako announced late on Monday that the US Food and Drug Administration has approved its HercepTest and HER2 FISH pharmDx as companion diagnostics for Genentech's breast cancer drug Perjeta (pertuzumab).

FDA also approved the drug.

Dako's assays will be used to identify patients with HER2-positive metastatic breast cancer who may be eligible for treatment with Perjeta and are available immediately.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.